Mavacamten for hypertrophic cardiomyopathy: Effectiveness and value

Mavacamten for hypertrophic cardiomyopathy: Effectiveness and value

Bibliographic Details
Main Authors: Beinfeld, M. (Author), Nhan, E. (Author), Pearson, S.D (Author), Rind, D.M (Author), Sarker, J. (Author), Walton, S. (Author), Wasfy, J.H (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2022
Subjects:
benzylamine derivative
Benzylamines
Cardiomyopathy, Hypertrophic
cost benefit analysis
Cost-Benefit Analysis
human
Humans
hypertrophic cardiomyopathy
MYK-461
United States
uracil
Uracil
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items